Search

Displaying results 4731 - 4740 of 5504 in total
  1. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  2. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    It is being devloped by Intercell AG for the treatment of hepatitis C. … The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.

  3. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial.

  4. Drug

    Friulimicin B

    go.drugbank.com/drugs/DB06087
    Investigational

    It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.

  5. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692]

  6. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  7. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range.

  8. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

  9. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072]

  10. Drug

    MD-0727

    go.drugbank.com/drugs/DB05948
    Investigational

    MD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.